Across TCGA pan-cancer cohorts, IGHG3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IGHG3 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IGHG3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated IGHG3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, UCEC, and PDAC are the cancer types where IGHG3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	All	1.000	0.107	.010	38	view →
UCEC	DFS	Quartile	All	0.720	1.000	<.001	28	view →
PDAC	DFS	Tertile	IV	0.217	0.749	.024	10	view →
CCRCC	DFS	Median	III,IV	0.399	0.932	.022	7	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	3	view →
LSCC	DFS	Median	All	0.937	0.608	.021	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: IGHG3 tumor-vs-normal RNA expression · all IGHG3 data types